๐น EPS: $4.88 (Est. $4.94) ๐ด; UP +102% YoY
๐น Revenue: $13.53B (Est. $13.66B) ๐ด; UP +45% YoY
๐น Net Income: $4.41B; UP +101% YoY
๐น Gross Profit Margin: 82.2% (Est. 81.62%) ๐ข
FY25 Guidance :
๐น Revenue: $58.0B - $61.0B (Est. $59.22B) ๐ก
๐น EPS: $22.05 - $23.55 (Est. $22.86) ๐ก
๐น Non-GAAP EPS: $22.50 - $24.00
๐น Gross Margin - OPEX / Revenue: 40.5% - 42.5% (Reported), 41.5% - 43.5% (Non-GAAP)
๐น Effective Tax Rate: ~16%
๐น Other Income (Expense): ($700M) - ($600M)
Key Product Q4 Performance:
๐น Zepbound: $1.91B
๐น Mounjaro: $3.53B; UP +60% YoY
๐น Verzenio: $1.56B; UP +36% YoY
๐น Jardiance: $1.20B; UP +50% YoY
๐น Trulicity: $1.25B; DOWN -25% YoY
๐น Taltz: $952M; UP +21% YoY
๐น Humalog: $619.9M; UP +69% YoY
Operational Metrics:
๐น COGS: $2.40B (Est. $2.51B) ๐ข
๐น Gross Profit: $11.13B (Est. $11.13B) ๐ก
๐น R&D Expenses: $3.02B (Est. $2.99B) ๐ก; UP +18% YoY
๐น SG&A Expenses: $2.42B (Est. $2.41B) ๐ก; UP +26% YoY
๐น Operating Expenses (R&D + SG&A): $5.44B (Est. $5.41B) ๐ก
Strategic & Business Developments:
๐ธ FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
๐ธ FDA approved Omvoh for moderately to severely active Crohn's disease.
๐ธ Positive SURMOUNT-5 trial results: Zepbound showed 47% greater weight loss vs. Wegovy.
๐ธ Announced pending acquisition of Scorpion Therapeutics' PI3Kฮฑ inhibitor program.
๐ธ $3B investment to expand Kenosha County, Wisconsin manufacturing facility.
๐ธ $15B share repurchase program announced alongside a 15% increase in quarterly dividend.
CEO David A. Ricks Commentary:
๐ธ "2024 was a highly successful year for Lilly with major data readouts, expanding manufacturing, and launching key products. We enter 2025 with strong momentum, focusing on sustained financial performance and critical Phase 3 readouts."